ENDRA Life Sciences (NDRA) Cash from Financing Activities (2016 - 2021)
Historic Cash from Financing Activities for ENDRA Life Sciences (NDRA) over the last 6 years, with Q4 2021 value amounting to $321076.0.
- ENDRA Life Sciences' Cash from Financing Activities fell 9423.77% to $321076.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $13.4 million, marking a year-over-year increase of 1285.52%. This contributed to the annual value of $7.8 million for FY2024, which is 386.54% up from last year.
- As of Q4 2021, ENDRA Life Sciences' Cash from Financing Activities stood at $321076.0, which was down 9423.77% from $496606.0 recorded in Q3 2021.
- In the past 5 years, ENDRA Life Sciences' Cash from Financing Activities registered a high of $12.6 million during Q1 2021, and its lowest value of $39238.0 during Q1 2020.
- Over the past 5 years, ENDRA Life Sciences' median Cash from Financing Activities value was $2.5 million (recorded in 2019), while the average stood at $3.9 million.
- Within the past 5 years, the most significant YoY rise in ENDRA Life Sciences' Cash from Financing Activities was 3197074.77% (2021), while the steepest drop was 9423.77% (2021).
- Over the past 5 years, ENDRA Life Sciences' Cash from Financing Activities (Quarter) stood at $8.5 million in 2017, then fell by 9.41% to $7.7 million in 2018, then decreased by 24.45% to $5.8 million in 2019, then decreased by 4.67% to $5.6 million in 2020, then plummeted by 94.24% to $321076.0 in 2021.
- Its Cash from Financing Activities stands at $321076.0 for Q4 2021, versus $496606.0 for Q3 2021 and $12.6 million for Q1 2021.